Efficacy and safety of liraglutide versus sitagliptin, both in combination with metformin, in Chinese patients with type 2 diabetes: a 26-week, open-label, randomized, active comparator clinical trial

Diabetes, Obesity and Metabolism

Volumn 18, Issue 8, 2016, Pages 803-811

  Zang, L ^a   Liu, Y ^b   Geng, J ^c   Luo, Y ^d   Bian, F ^e   Lv, X ^a   Yang, J ^f   Liu, J ^g   Peng, Y ^h   Li, Y ⁱ   Sun, Y ^j   Bosch Traberg, H ^k   Mu, Y ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b THE SECOND HOSPITAL OF JILIN UNIVERSITY   (China)

^c HARRISON INTERNATIONAL PEACE HOSPITAL   (China)

^d CHONGQING THREE GORGES UNIVERSITY   (China)

^e People Hospital of Cangzhou   (China)

^f The Central Hospital of Minhang District   (China)

^g Urology Institute of Fudan University   (China)

^h SHANGHAI FIRST PEOPLE S HOSPITAL   (China)

ⁱ HEBEI MEDICAL UNIVERSITY   (China)

^j SIBS Novo Nordisk Translational Research Centre for PreDiabetes   (China)

^k NOVO NORDISK A S   (Denmark)

more..

Author keywords

Chinese; liraglutide; sitagliptin; type 2 diabetes

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; LIRAGLUTIDE; METFORMIN; SITAGLIPTIN; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ADD ON THERAPY; ADULT; ADVERSE OUTCOME; AGED; ARTICLE; ATRIAL FIBRILLATION; BRONCHITIS; CHINESE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DECREASED APPETITE; DIABETIC KETOACIDOSIS; DIARRHEA; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; GLUCOSE BLOOD LEVEL; HEMORRHOID; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; STOMACH ULCER; SUDDEN DEAFNESS; THYMOMA; THYROID CANCER; WEIGHT REDUCTION; ADOLESCENT; ANOREXIA; ASIAN CONTINENTAL ANCESTRY GROUP; BODY WEIGHT; CHEMICALLY INDUCED; CHINA; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; DIABETES MELLITUS, TYPE 2; DIET RESTRICTION; HYPOGLYCEMIA; METABOLISM; MIDDLE AGED; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANOREXIA; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD GLUCOSE; BODY WEIGHT; CHINA; DIABETES MELLITUS, TYPE 2; DIARRHEA; DRUG THERAPY, COMBINATION; FASTING; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; LIRAGLUTIDE; MALE; METFORMIN; MIDDLE AGED; NAUSEA; SITAGLIPTIN PHOSPHATE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84970990680     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12674     Document Type: Article

References (41)

1. Yang W, Lu J, Weng J et al. Prevalence of diabetes among men and women in China. N Engl J Med 2010; 362: 1090–1101.
2. Xu Y, Wang L, He J et al. Prevalence and control of diabetes in Chinese adults. JAMA 2013; 310: 948–959.
3. Inzucchi SE, Bergenstal RM, Buse JB et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015; 38: 140–149.
4. Hayward RA, Reaven PD, Wiitala WL et al. Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2015; 372: 2197–2206. Erratum in: N Engl J Med 2015; 373: 198.
5. Ji LN, Lu JM, Guo XH et al. Glycemic control among patients in China with type 2 diabetes mellitus receiving oral drugs or injectables. BMC Public Health 2013; 13: 602.
6. Cooperative Meta-analysis Group of the Working Group on Obesity in China. Predictive value of body mass index and waist circumference for risk factors of certain related diseases in Chinese adults—study on optimal cut-off points of body mass index and waist circumference in Chinese adults. Biomed Environ Sci 2002; 15: 83–95.
7. Wing RR, Lang W, Wadden TA et al., Look AHEAD Research Group. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care 2011; 34: 1481–1486.
8. Vilsbøll T, Garber AJ. Non-glycaemic effects mediated via GLP-1 receptor agonists and the potential for exploiting these for therapeutic benefit: focus on liraglutide. Diabetes Obes Metab 2012; 14(Suppl. 2): 41–49.
9. Nauck M. Incretin therapies–highlighting common features and differences in the modes of action of GLP-1 receptor agonists and DPP-4 inhibitors. Diabetes Obes Metab 2016; 18: 203–216.
10. Pratley RE, Nauck M, Bailey T et al. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet 2010; 375: 1447–1456.
11. Pratley R, Nauck M, Bailey T et al. One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial. Int J Clin Pract 2011; 65: 397–407.
12. Yang W, Chen L, Ji Q et al. Liraglutide provides similar glycaemic control as glimepiride (both in combination with metformin) and reduces body weight and systolic blood pressure in Asian population with type 2 diabetes from China, South Korea and India: a 16-week, randomized, double-blind, active control trial(*). Diabetes Obes Metab 2011; 13: 81–88.
13. Yang W, Guan Y, Shentu Y et al. The addition of sitagliptin to ongoing metformin therapy significantly improves glycemic control in Chinese patients with type 2 diabetes. J Diabetes 2012; 4: 227–237.
14. World Medical Association. Declaration of Helsinki-Ethical principles for medical research involving human subjects. Last Amended by the 59th WMA General Assembly, Seoul, 2008.
15. International Conference on Harmonisation. ICH harmonised tripartite guideline. Good clinical practice, 1 May 1996. Available from URL: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6/E6_R1_Guideline.pdf. Accessed December 2015.
16. EMC. Victoza Summary of Product Characteristics. Available from URL: https://www.medicines.org.uk/emc/medicine/21986. Accessed 03 May 2016.
17. Federal Drug Agency (FDA). FDA guidance for industry, diabetes mellitus: developing drugs and therapeutic biologics for treatment and prevention, 2008. Available from URL: http://www.fda.gov/downloads/Drugs/…/Guidances/ucm071624.pdf. Accessed 03 May 2016.
18. Chinese Diabetes Society. Chinese guideline for the management of type 2 diabetes mellitus (2013 edition). Chin J Diabetes Mellitus 2014; 6: 447–498. Accessed 03 May 2016.
19. Kim YG, Hahn S, Oh TJ, Park KS, Cho YM. Differences in the HbA1c-lowering efficacy of glucagon-like peptide-1 analogues between Asians and non-Asians: a systematic review and meta-analysis. Diabetes Obes Metab 2014; 16: 900–909.
20. Marre M, Shaw J, Brändle M et al. LEAD-1 SU study group. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabet Med 2009; 26: 268–278.
21. Nauck M, Frid A, Hermansen K et al. LEAD-2 study group. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care 2009; 32: 84–90.
22. Garber A, Henry R, Ratner R et al. LEAD-3 (Mono) Study Group. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009; 373: 473–481.
23. Zinman B, Gerich J, Buse JB et al. LEAD-4 study investigators. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care 2009; 32: 1224–1230.
24. Russell-Jones D, Vaag A, Schmitz O et al. Liraglutide effect and action in diabetes 5 (LEAD-5) met + SU study group. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met + SU): a randomised controlled trial. Diabetologia 2009; 52: 2046–2055.
25. Buse JB, Rosenstock J, Sesti G et al. LEAD-6 study group. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009; 374: 39–47.
26. Craddy P, Palin HJ, Johnson KI. Comparative effectiveness of dipeptidylpeptidase-4 inhibitors in type 2 diabetes: a systematic review and mixed treatment comparison. Diabetes Ther 2014; 5: 1–41.
27. Shyangdan DS, Royle PL, Clar C, Sharma P, Waugh NR, Snaith A. Glucagon-like peptide analogues for type 2 diabetes mellitus. Cochrane Database Syst Rev 2011; 10: CD006423.
28. Bloomgarden ZT. Diabetes and obesity: part 1. Diabetes Care 2007; 30: 3145–3151.
29. Bloomgarden ZT. Diabetes and obesity: part 2. Diabetes Care 2008; 31: 176–182.
30. Niswender K, Pi-Sunyer X, Buse J et al. Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme. Diabetes Obes Metab 2013; 15: 42–54.
31. Meier JJ. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol 2012; 8: 728–742.
32. Blonde L, Russell-Jones D. The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1-5 studies. Diabetes Obes Metab 2009; 11(Suppl. 3): 26–34.
33. Pratley RE, Nauck MA, Barnett AH et al. Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study. Lancet Diabetes Endocrinol 2014; 2: 289–297.
34. Meier JJ, Rosenstock J, Hincelin-Méry A et al. Contrasting effects of lixisenatide and liraglutide on postprandial glycemic control, gastric emptying, and safety parameters in patients with type 2 diabetes on optimized insulin glargine with or without metformin: a randomized, open-label trial. Diabetes Care 2015; 38: 1263–1273.
35. Dungan KM, Povedano ST, Forst T et al. Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial. Lancet 2014; 384: 1349–1357.
36. Pyke C, Heller RS, Kirk RK et al. GLP-1 provoked severe hypoglycemia in an individual with type 2 diabetes and a benign insulinoma. Diabetes Care 2014; 37: e177–e178.
37. Marso SP, Poulter NR, Nissen SE et al. Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial. Am Heart J 2013; 166: 823–830.
38. Steinberg WM, Nauck MA, Zinman B et al. LEADER 3–lipase and amylase activity in subjects with type 2 diabetes: baseline data from over 9000 subjects in the LEADER Trial. Pancreas 2014; 43: 1223–1231.
39. Lando HM, Alattar M, Dua AP. Elevated amylase and lipase levels in patients using glucagonlike peptide-1 receptor agonists or dipeptidyl-peptidase-4 inhibitors in the outpatient setting. Endocr Pract 2012; 18: 472–477.
40. Tokuyama H, Kawamura H, Fujimoto M et al. A low-grade increase of serum pancreatic exocrine enzyme levels by dipeptidyl peptidase-4 inhibitor in patients with type 2 diabetes. Diabetes Res Clin Pract 2013; 100: e66–e69.
41. Yang W, Weng J. Early therapy for type 2 diabetes in China. Lancet Diabetes Endocrinol 2014; 2: 992–1002.